Vaccination in the prevention of infectious respiratory diseases in adults

Brazilian Society of Pneumology and Tisiology

Final Elaboration: December 21st, 2012

Participants: Fernando Lundgren, Bernardo Maranhão, Ricardo Martins, José Miguel Chatkin, Marcelo Fouad Rabahi MF, Ricardo Amorim Corrêa, Maria Rúbia F. de Figueiredo, Nathalia Carvalho Andrade, Roberto Stibulov

Description of the evidence collection method:
Active searches were made on the Pubmed/MEDLINE, Scielo/LILACS and Cochrane Library databases, using the following descriptive terms (MeSH terms): Vaccines, Vaccination, Immunization, Immunization Schedule*, Immunization Programs, Mass vaccination, Vaccines, Inactivated; Vaccines Attenuated; Vaccines, Synthetic; Antiviral Agents, Antibodies, Viral; Virus Shedding*, Disease Notification, Disease Outbreaks, Influenza Vaccines, Influenza A Virus, Influenza, Human/prevention & control, Bacterial Vaccines, Vaccines, Acellular; Antibiotics, Bacterial; Diphtheria Vaccine, Pertussis Vaccine, Bordetella pertussis*, Diphtheria/prevention & control; Whooping Cough; Vaccines, Combined; DTTP vaccine, Diphtheria-Tetanus-Pertussis Vaccine, Diphtheria Tetanus acellular Pertussis Vaccines, Tetanus, Poliovirus Vaccine, Inactivated; BCG Vaccine, Tuberculin Test, Tuberculosis, Pulmonary/prevention & control, Tuberculosis, Tuberculosis, Pulmonary, Pulmonary; Pneumococcal Vaccines, Streptococcal Vaccines, Pneumococcal Infection/prevention & control, 23-valente pneumococcal capsular polysaccharide vaccine, heptavalent pneumococcal conjugate vaccine, Splenectomy, Diabetes Mellitus, Diabetes Complications, Anemia, Sickle Cell, Hemoglobinopathies, Pulmonary Disease, Chronic Obstructive; HIV Infections, HIV Seropositivity, AIDS, Acquired Immunodeficiency Syndrome, Cerebrospinal Fluid Rhinorrhea, cerebrospinal fluid leak (CSF), Smoking, Alcohol-Related Disorders, Alcoholism, complications, bacteriaemia, Liver Cirrhosis, Alcoholic, Immunosuppression, Dose-Response Relationship, Immunologic, Immunizations Programs, Immunization, Secondary; Patient Participation, Dose-Response Relationship, Immunologic; Risk, administration & dosage*, adverse effects*, mortality, Cost-Benefit Analysis, Injections, Intramuscular; Injections, Intradermal; administration, intranasal; utilization, prevention & control; Immunity, Maternally-Acquired; Pregnancy, Pregnancy Complications, Infectious.

Level of recommendation and strength of evidence:
A: Experimental or observational studies with better consistency.
B: Experimental or observational studies with lower consistency.
C: Case reports (uncontrolled studies).
D: Opinion without critical evaluation, based on consensus, physiological studies or animal models.

Objective
To present alternatives to existing vaccines for the prevention of infectious respiratory diseases in adults, with their recommendations, adverse effects and contraindications.

Conflict of interest
The conflicts of interest declared by the participants in the elaboration of these guidelines are detailed on page 12.

Introduction
Despite the large advancements in Public Health resulting from immunization, there are still deaths or illness caused by diseases that could be prevented using vaccines.

Vaccination, initially focused exclusively on the child and adolescent range, was extended to all ages. The adult and elderly immunization schedule of the National Adult and Elderly Vaccination Program from the Ministry of Health (MH) is presented below (Table 1), and includes some of the vaccines, such as hepatitis and yellow fever immunization, since the focus is on the prevention of respiratory diseases in adults and the elderly.
The vaccines used in adults for the prevention of infectious diseases include four diseases with a high level of invasiveness and morbidity, which contribute to increasing mortality in our patients.

1 - Vaccine against the influenza virus
2 - Vaccine against pertussis
3 - Vaccine against tuberculosis
4 - Vaccine against *Streptococcus pneumoniae*

**IS THERE A BENEFIT TO THE USE OF FLU VACCINES?**

Flu symptoms are mostly caused by the influenza virus, notably types A and B, the latter on a lower scale.

The high rate of mutation of the virus’ antigenic structure contributes to increasing the annual incidence of the disease at determined times of the year, and justifies the need for annual vaccination, since the protection given by the flu vaccine is temporary\(^7\). Cases of flu used to occur at cold times of the year. In the north region of Brazil, they occur mostly in the rainy period, which coincides with the winter in the Northern Hemisphere (December to February). In the other regions of the country, the peak incidence occurs between May and August. This variability continually challenges the immunological system to carry out its defensive role against the aggression of new variants of the virus circulating in the community. The incidence of hospitalization owing to complications resulting from influenza is 0.8 (CI 95% 0.1-1.15) per 1000 people/year in the age range 18-49 years, and 1.06 (CI 95% 7.5-13.6) per 1000 people/year in patients over 65 years\(^8\).

Aware of this information, specialists coordinated by the US Centers for Disease Control (CDC) and the World Health Organization (WHO) met to decide, based on data derived from sentinel laboratories spread all over the world, on the composition of the flu vaccine to be given from May to October in the Southern Hemisphere and from November to April in the Northern Hemisphere\(^1,4-6\).

The vaccine used in Brazil is the trivalent type, with inactivated fragmented viral particles\(^7\), with a recommended adult dose of 0.5 mL intramuscularly in the deltoid region.

Inactive seasonal flu vaccines have been used since 1940\(^9\). The vaccine is inactivated using formaldehyde, uses thimerosal as a preservative and is produced by viral growth in embryonated chicken eggs. Given the greater power of mutation of type A, the composition of the vaccine normally contains two antigenic variants of type A and one variant of type B. There is a benefit to the use of inactivated trivalent vaccine in relation to the attenuated vaccine. The inactivated form leads to a higher num-

---

**TABLE 1** Vaccination calendar for adults and the elderly

<table>
<thead>
<tr>
<th>Age</th>
<th>Vaccine</th>
<th>Dose</th>
<th>Diseases avoided</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 to 59 years</td>
<td><em>Hepatitis B</em> (vulnerable groups)</td>
<td>Three doses</td>
<td>Hepatitis B</td>
</tr>
<tr>
<td></td>
<td><em>Hepatitis B</em> vaccine (recombinant)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Double, adult type (dT)</em></td>
<td>One dose every ten years</td>
<td>Diphtheria and tetanus</td>
</tr>
<tr>
<td></td>
<td><em>Adult diphtheria and tetanus vaccine</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Yellow fever</em> (attenuated)</td>
<td>One dose every ten years</td>
<td>Yellow fever</td>
</tr>
<tr>
<td></td>
<td><em>Yellow fever vaccine</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Triple vaccine (MMR)</em></td>
<td>Single dose</td>
<td>Measles, mumps and rubella</td>
</tr>
<tr>
<td></td>
<td><em>Measles, mumps and rubella vaccine</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 years or more</td>
<td><em>Hepatitis B</em> (vulnerable groups)</td>
<td>Three doses</td>
<td>Hepatitis B</td>
</tr>
<tr>
<td></td>
<td><em>Hepatitis B</em> vaccine (recombinant)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Yellow fever</em> (attenuated)</td>
<td>One dose every ten years</td>
<td>Yellow fever</td>
</tr>
<tr>
<td></td>
<td><em>Yellow fever vaccine</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Seasonal influenza</em></td>
<td>Annual dose</td>
<td>Seasonal influenza</td>
</tr>
<tr>
<td></td>
<td><em>Influenza vaccine (fractional inactivated)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>23-valent pneumococcal (Pn23)</em></td>
<td>Single dose</td>
<td>Infections caused by Pneumococcus</td>
</tr>
<tr>
<td></td>
<td><em>23-valent pneumococcal vaccine (polysaccharide)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Double, adult type (dT)</em></td>
<td>One dose every ten years</td>
<td>Diphtheria and tetanus</td>
</tr>
<tr>
<td></td>
<td><em>Adult diphtheria and tetanus vaccine</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ADULT AND ELDERLY VACCINATION CALENDAR\(^2\)(D).

Note: Maintained the nomenclature of the National Immunization Program and inserted the nomenclature according to the Collegiate Directorship Resolution– RDC n. 61, August 25th 2008 – Brazilian Sanitary Surveillance Agency (ANVISA).
ber of serum antibodies and there is a tendency for a lower number of vaccine reactions (0.5% versus 0.8%), but with no significant differences. Patients immunized with inactivated vaccine that subsequently develop flu symptoms have lower fever intensity6(B).

The vaccine is formally contraindicated for individuals allergic to eggs or egg derivatives or who have presented allergies to previous doses. For patients with previous diagnosis of Guillain-Barré syndrome, the use of the vaccine should be studied carefully8(D). There is also voluntary refusal of the vaccine, even in patients considered as high risk10(B).

In general, the use of inactivated vaccine is well tolerated, few collateral effects being described. Pain in the vaccination site is the most frequent adverse effect, potentially reaching 46% of injections. Low intensity fever and light systemic symptoms such as fatigue (24%), headache (19%) and myalgia (18%) may occur 8 to 24 hours after immunization11(A).

The medical literature has demonstrated that the systematic use of flu vaccines does not decrease the prevalence of the clinical symptoms of flu12-13(D), however it causes a significant reduction in cases of pneumonia, hospital admissions and death caused by the illness. There is a fall of 27%14(B) to 32%15(B) in the number of hospitalizations for pneumonia or flu, and a reduction of 37%16(B), 45%17(B), 48%14-17(B), and even 50%17(B) in the risk of death for all causes in the winter14(B). It also reduces the number of office visits (17% for pneumonia or flu and 6.4% for visits due to any respiratory condition) as well as reducing the cost of hospitalization by 30.7%15(B). Flu vaccines reduce the risk of hospitalization for cardiac diseases by 19% (p<0.001), and between 16 and 23% for cerebrovascular diseases (p<0.018 and p<0.001, respectively)17-18(B), as well as reducing mortality for cardiac causes in 37% of the cases16-18(B).

In principle, any person over 6 months of age can use the vaccine annually; however, in general, on account of limited stocks, it is recommended for the vaccine to be administered preferably to the following groups of people6(D):

1. Individuals over 50 years;
2. Residents of orphanages or nursing homes;
3. Patients that present chronic cardiovascular or pulmonary diseases, including asthma;
4. Patients with chronic metabolic diseases, such as diabetes mellitus, hepatic, renal and hematological diseases;
5. Patients with immunosuppression;
6. Patients with neurological or neuromuscular diseases that could compromise their pulmonary defenses;
7. Pregnant women or those of fertile age;
8. Workers in the healthcare area;
9. Individuals of indigenous ethnicity;
10. Individuals with obesity at advanced levels;
11. Children aged from 6 months to 5 years.

**Recommendation**

The flu vaccine available in Brazil is the trivalent type with fragmented and inactivated viral particles, whose application should be done intramuscularly and annually. The use of the flu vaccine is indicated for special groups of adults1-4-7(D). The vaccine does not reduce the clinical symptoms of the illness, but enables significant reductions in pneumonias, hospital admissions and death caused by flu14(B)12-13(D). It is formally contraindicated in individuals allergic to eggs or egg derivatives and to those who have displayed allergies in previous doses8(D).

**IS THERE BENEFIT TO THE USE OF PERTUSSIS VACCINES?**

There are three vaccines against whooping cough for adults licensed in Brazil19-21(D). These vaccines are only available in private services22(D).

The first vaccine, licensed in 2001, is composed of a combination of three components against diphtheria, tetanus and acellular pertussis (dTpa)19(D). The other two vaccines were licensed in Brazil in 2011 but being used at a global level since 200520-21(D). Both combine components against diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis (dTpa-IPV20-21(D).

**TABLE 2** The antigen compositions in the vaccines19-21(D)23(B)

<table>
<thead>
<tr>
<th>Antigens</th>
<th>dTpa19(D)</th>
<th>dTpa-IPV20(D)</th>
<th>dTpa-IPV21(D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT (µg)</td>
<td>8</td>
<td>8</td>
<td>2,5</td>
</tr>
<tr>
<td>HAF (µg)</td>
<td>8</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>PRN (µg)</td>
<td>2,5</td>
<td>2,5</td>
<td>3</td>
</tr>
<tr>
<td>FIM 2 + 3 (µg)</td>
<td>-</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>D (Lf)</td>
<td>2,5</td>
<td>2 (≥2UI)</td>
<td>2 (≥2UI)</td>
</tr>
<tr>
<td>T (Lf)</td>
<td>5</td>
<td>5 (≥20UI)</td>
<td>5 (≥20UI)</td>
</tr>
<tr>
<td>Pòlio (D-Ag-U)</td>
<td>-</td>
<td>40D</td>
<td>40D</td>
</tr>
<tr>
<td>1</td>
<td>8D</td>
<td>8D</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>8D</td>
<td>8D</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>32D</td>
<td>32D</td>
<td></td>
</tr>
</tbody>
</table>

D = diphtheria toxoid; FIM 2 + 3 = fimbrue 2 and 3; FHA Filamentous haemagglutinin; LF = Floculation polioensur virus limena; Polio = 1,2 and 3 polo vaccination; PRN = Pertactin; PT =pertussis toxin; T = Tetanus toxoid.
All of the vaccines have aluminum phosphate adjuvant and 2-phenoxyethanol and polysorbate 80 excipients. The vaccines may contain traces of neomycin, streptomycin, polymyxin B, glutaraldehyde and formaldehyde. They are presented in the form of a suspension, in single dose syringes of 0.5 mL, ready to use.

It is recommended for booster vaccination against diphtheria, tetanus and whooping cough, as between the decades of 1970 and 1980 there were resurgences of whooping cough in various parts of the world, resulting from the low presence of antibodies for these diseases in individuals over 40 years, even in patients that completed the full basic vaccination scheme. Brazil, like the whole of Latin America, has maintained the certificate granted by the WHO for eradication of the poliomyelitis virus.

Administration should be intramuscular, preferably in the deltoid muscle, and may be applied from the age of 11 years, that is, the vaccine may be given to adolescents, adults and the elderly.

The recommended vaccination schedule depends on three situations of the vaccine status.

1° If the basic vaccination scheme is complete - substitute the booster dose of dT with dTpa or dTpa-IPV. If the individual has already received the booster dose with adult diphtheria or tetanus or adult double bacteria (dT), there is no need for an interval of the dose with dTpa or dTpa-IPV as a booster for the diseases not covered in the dTpa-IPV (D).

2° If the basic vaccination scheme is incomplete (one or two doses of the tetanic component received over the lifespan) – complete the scheme of 3 doses by applying:

- One dose of dTpa or dTpa-IPV if there are two previous doses of the tetanic component (D);
- One dose of dTpa or dTpa-IPV and, after a minimum interval of 2 months, another dose of dT, if a previous dose of the tetanic component was received (D).

3° If the vaccination scheme has not been carried out or is unknown - proceed with vaccination at an interval of 0, 2, and 6 months. With the first dose of dTpa or dTpa-IPV and subsequent doses with dT (D).

In special situations, the interval between the 1st and 2nd doses may be reduced to 1 month, between the 2nd and 3rd doses, maintain the interval of 6 to 12 months.

The vaccination against whooping cough is especially recommended in adults that live with or care for infants aged less than one year, given they are the main transmitters of Bordetella pertussis to this group (D). Health professionals, especially those operating in newborn, pediatric, geriatric and oncology units should also be vaccinated (D).

Only in September of 2011, the use of the anti-pertussis vaccine in patients aged over 65 years was cleared by the U.S. Food and Drug Administration (FDA), as well as for patients with special clinical conditions such as chronic pneumonia, heart disease, diabetes, HIV or other immuno-deficiency conditions, chronic liver diseases, chronic alcoholism, asplenia and kidney failure. It is known that the morbidity of the disease is higher in these groups. Reinforcement with dTPa or dTPa-IPV induces a better immunological response in adults between 55 and 64 years of age than those aged over 65, with a larger population and greater follow-up time necessary to evaluate the results in the latter population (D).

Some studies are evaluating the safety and importance of vaccination in pregnant women. The Brazilian Immunization Association (SBIm) and the Advisory Committee on Immunization Practices in the USA (ACIP) suggest for the vaccine to be given after the 20th week of pregnancy, or post-partum, if the mother has not been vaccinated previously, while there is no clearance on the vaccines for this specific group.

The vaccines are effective and immunogenic, and various studies have shown satisfactory antibody production response at the booster dose. This data may be correlated with an effective clinical protection response against whooping cough (A).

In 2004, after some provinces in Canada introduced dTpa with a fifth component (Haemophilus influenzae type B) in adolescents between 14 and 16 years, an important reduction of 84% was observed in the disease in this age range, as well as groups with a lower age range, due to the probable effect of herd immunity.

In the same year, Australia introduced a booster with dTpa for adolescents between 15 and 17 years. However, owing to the elevated incidence of the disease in adolescents, some states such as New South Wales expanded the age range of the immunization program to 12 to 17 years and noted an effectiveness of 78% (CI 95% 60.7-87.6), that is, the disease was reduced from 124 to 40.4/100,000 (B). It was therefore shown that the booster dose could be used as an effective tool to control the disease (A).

In relation to the adverse effects of anti-pertussis vaccines for adults, there is a very similar safety profile to that observed in the dT vaccine, which is widely used in the national immunization program (D). The most
common adverse effects are local reactions such as pain (61 to 69.2%), edema (17.6 to 25.6%) and erythema (21.1 to 27.1%)\(^5(\text{B})\). Systemic adverse effects may occur, such as headache (30 to 31%), body temperature above 37.5°C (5.5 to 8%), fatigue (28.1 to 28.9%), and gastrointestinal symptoms (15.9 to 17.5%)\(^6(\text{B})\).

The vaccines are contraindicated in cases of allergies of an anaphylactic nature to previous vaccinations or to any of the components of the vaccine\(^7(\text{D})\). People with previous cases of encephalopathy without an identifiable cause in a 7-day period after the previous dose of vaccines containing pertussis components should only receive dT\(^7(\text{D})\).

**Recommendation**

The anti-pertussis vaccines available in Brazil are acellular and present components against diphtheria, tetanus and whooping cough (dTpa)\(^8(\text{D})\) or components against diphtheria, tetanus, whooping cough and inactivated polio (dTpa-IPV)\(^9(\text{D})\). The booster vaccine depends on the situation of the basic vaccine status in childhood\(^10(\text{D})\) and is recommended because the antibodies of these diseases are low in individuals over 40 years\(^11(\text{B})\). Adults that live or work with infants less than one year old should receive a single booster\(^12(\text{B})\). This therapeutic resource was only cleared for the elderly with chronic diseases in 2011\(^13(\text{B})\) and, preliminary results demonstrate better immunological response for adults between 55 and 64 years\(^14(\text{B})\). It should be remembered that Brazil has maintained the eradication of the poliomyelitis disease for years\(^15(\text{B})\) and, as the effective clinical protection of anti-pertussis vaccines is against whooping cough\(^16(\text{A})\), it is recommended to use dTpa\(^17(\text{D})\), as there would be no greater benefit in using the combined vaccine with inactivated poliomyelitis (dTpa-IPV)\(^18(\text{D})\). They are contraindicated in the case of previous anaphylactic allergic reaction to the vaccination or any component of the vaccine\(^19(\text{D})\).

**IS THERE A BENEFIT TO THE USE OF BCG VACCINES?**

The BCG (Bacille de Calmette et Guérin) vaccine originates from attenuated and avirulent strains of *Mycobacterium bovis*, which through immunogenic properties are able to stimulate protection against serious infection and illness caused by *Mycobacterium tuberculosis*, such as tuberculous meningitis and miliary tuberculosis. It has been used since 1921\(^20(\text{B})\).

The existing recommendation is for newborns up to the first month old. The loss of the protective effect of the BCG vaccine over time has led to some countries adopting revaccination\(^21(\text{B})\). In Brazil, the Ministry of Health has recommended the BCG revaccination of the 6- to 14-year population since 1994. Nevertheless, studies on BCG revaccination (including in Brazil) has not shown protection by the second dose against tuberculosis in revaccinated adolescents\(^22(\text{B})\).

BCG revaccination has been studied in both populations with persistent protective effects as well as those where the protective effects was lost, with no differences between the groups. The incidence of tuberculosis was 16.5 and 12.9 per 100,000 people/year in vaccinated and revaccinated people respectively, without significant differences, as the reduction of the risk upon revaccination had RR = 1.28 with CI 95% 0.92-1.77\(^23(\text{B})\). In Brazil, the incidence of tuberculosis between those vaccinated according to the usual calendar and those revaccinated is greater without the booster, but maintains the absence of benefit, with 29.3 versus 30.2 per 100,000 people/year, with RR=0.94 and CI 95% 0.76-1.28\(^24(\text{B})\). It would be necessary to immunize 4963 people to avoid the development of one case of tuberculosis, therefore, there is no adequate cost-benefit relationship\(^25(\text{B})\).

Thus, in 2006, the Ministry of Health recommended the suspension of BCG revaccination. It is also not recommended to revaccinate the indigenous population. Therefore, in adults, only those in contact with leprosy should be revaccinated, and, even then, only once\(^26(\text{D})\). Currently in Brazil, the only recommendation in adults relates to household contact with leprosy patients\(^27(\text{B})\).

The possibility of a secondary vaccination of BCG for those with HIV is still being evaluated, with the benefits yet to be proven\(^28(\text{B})\).

The dose and frequency of application is two doses of 0.1 mL each, with a 6 month interval between them. Each 0.1 mL dose of reconstituted intradermic BCG vaccine contains:

- Bacille de Calmette et Guérin ----------- 0.1 mg
- Sodium glutamate------------------0.52 mg
- Saline solution at 0.9% (q.s.p.)-----0.1 mL

The adverse effects of the application of BCG vaccine are rare and generally occur due to incorrect application, such as too deep or using an excessive dose of the immunobiological component. In up to 10% of people vaccinated the formation of an ulcerate lesion occurs, which may take months to heal completely. Other presentations include abscess at the injection site and floating nodes with fistulization, osteitis, osteomyelitis, and generalized infection may possibly occur. Serious allergic reactions (anaphylaxis) are rare.

---

\(^1\) Lundsø F et al.
\(^2\) The BCG (Bacille de Calmette et Guérin) vaccine orig
\(^3\) They are contraindicated in the case of previous anaphylactic
\(^4\) \text{B}^{(\text{B})}
\(^5\) Systemic adverse effects may occur, such as headache (30 to 31%
\(^6\) Body temperature above 37.5°C (5.5 to 8%), fatigue (28.1 to 28.9%
\(^7\) \text{D}^{(\text{D})}
\(^8\) The vaccines are contraindicated in cases of allergies of an anaphylactic nature to previous vaccinations or to any of the components of the vaccine\(^7(\text{D})\).
\(^9\) People with previous cases of encephalopathy without an identifiable cause in a 7-day period after the previous dose of vaccines containing pertussis components should only receive dT\(^7(\text{D})\).
\(^10\) \text{D}^{(\text{D})}
\(^11\) Adults that live or work with infants less than one year old should receive a single booster\(^12(\text{B})\).
\(^12\) This therapeutic resource was only cleared for the elderly with chronic diseases in 2011\(^13(\text{B})\).
\(^13\) and, preliminary results demonstrate better immunological response for adults between 55 and 64 years\(^14(\text{B})\).
\(^14\) It should be remembered that Brazil has maintained the eradication of the poliomyelitis disease for years\(^15(\text{B})\) and, as the effective clinical protection of anti-pertussis vaccines is against whooping cough\(^16(\text{A})\), it is recommended to use dTpa\(^17(\text{D})\), as there would be no greater benefit in using the combined vaccine with inactivated poliomyelitis (dTpa-IPV)\(^18(\text{D})\). They are contraindicated in the case of previous anaphylactic allergic reaction to the vaccination or any component of the vaccine\(^19(\text{D})\).
\(^15\) \text{D}^{(\text{D})}
\(^16\) IS THERE A BENEFIT TO THE USE OF BCG VACCINES?
\(^17\) The BCG (Bacille de Calmette et Guérin) vaccine originates from attenuated and avirulent strains of *Mycobacterium bovis*, which through immunogenic properties are able to stimulate protection against serious infection and illness caused by *Mycobacterium tuberculosis*, such as tuberculous meningitis and miliary tuberculosis. It has been used since 1921\(^20(\text{B})\).
\(^18\) The existing recommendation is for newborns up to the first month old. The loss of the protective effect of the BCG vaccine over time has led to some countries adopting revaccination\(^21(\text{B})\). In Brazil, the Ministry of Health has recommended the BCG revaccination of the 6- to 14-year population since 1994. Nevertheless, studies on BCG revaccination (including in Brazil) has not shown protection by the second dose against tuberculosis in revaccinated adolescents\(^22(\text{B})\).
\(^19\) BCG revaccination has been studied in both populations with persistent protective effects as well as those where the protective effects was lost, with no differences between the groups. The incidence of tuberculosis was 16.5 and 12.9 per 100,000 people/year in vaccinated and revaccinated people respectively, without significant differences, as the reduction of the risk upon revaccination had RR = 1.28 with CI 95% 0.92-1.77\(^23(\text{B})\).
\(^20\) In Brazil, the incidence of tuberculosis between those vaccinated according to the usual calendar and those revaccinated is greater without the booster, but maintains the absence of benefit, with 29.3 versus 30.2 per 100,000 people/year, with RR=0.94 and CI 95% 0.76-1.28\(^24(\text{B})\).
\(^21\) It would be necessary to immunize 4963 people to avoid the development of one case of tuberculosis, therefore, there is no adequate cost-benefit relationship\(^25(\text{B})\).
\(^22\) Thus, in 2006, the Ministry of Health recommended the suspension of BCG revaccination. It is also not recommended to revaccinate the indigenous population. Therefore, in adults, only those in contact with leprosy should be revaccinated, and, even then, only once\(^26(\text{D})\).
\(^23\) Currently in Brazil, the only recommendation in adults relates to household contact with leprosy patients\(^27(\text{B})\).
\(^24\) The possibility of a secondary vaccination of BCG for those with HIV is still being evaluated, with the benefits yet to be proven\(^28(\text{B})\).
\(^25\) The dose and frequency of application is two doses of 0.1 mL each, with a 6 month interval between them. Each 0.1 mL dose of reconstituted intradermic BCG vaccine contains:

- Bacille de Calmette et Guérin ----------- 0.1 mg
- Sodium glutamate------------------0.52 mg
- Saline solution at 0.9% (q.s.p.)-----0.1 mL

\(^26\) The adverse effects of the application of BCG vaccine are rare and generally occur due to incorrect application, such as too deep or using an excessive dose of the immunobiological component. In up to 10% of people vaccinated the formation of an ulcerate lesion occurs, which may take months to heal completely. Other presentations include abscess at the injection site and floating nodes with fistulization, osteitis, osteomyelitis, and generalized infection may possibly occur. Serious allergic reactions (anaphylaxis) are rare.
Recommendations
The BCG is recommended for newborns and infants aged up to one month at two doses of 0.1 mL, at 6 months intervals.

The BCG vaccine has few adverse effects, generally resulting from incorrect application. Currently in Brazil, the only recommendation for adults relates to household contact with leprosy patients.

Which pneumococcal vaccines are available in Brazil?
There are currently two types of vaccine employing different technologies. The first type of vaccine is the 23-valent polysaccharide (VPPS-23) vaccine, an unconjugated formulation that has antigens to the walls of 23 serotypes. These are responsible for around 90% of the strains implicated in invasive pneumococcal disease (IPD), and the vaccine was developed primarily for use in adults.

The second type available uses a carrier protein conjugated to the vaccine’s polysaccharide antigens, and is therefore denominated a conjugate vaccine. This combination increases the immunogenic effect and duration of the immunological memory, providing longer lasting protection. Two new formulations conjugated with antigens of 10 (PCV10) and 13 (PCV13) serotypes were approved in Brazil for the prevention of IPD in children aged up to two years of age (PCV10) and children aged between two months and six years (PCV13). PCV13 has already been approved for use in adults in the European Community and some countries in Latin America, and was cleared by the FDA in September 2011, and by the ANVISA, in Brazil, in 2013.

The polysaccharide vaccine is widely used in adults and the elderly. It produces a short immune response with low permanence for the production of antibodies, mainly after 65 years of age. In some specific populations, revaccination was attempted five years after the first dose, without satisfactory results, as the improvement in the level of antibodies is transitory, with possible hyporesponsiveness. While conjugate vaccines are habitually used in children less than 2 years old, they may also be applied in adults, stimulating the immune response with the production of antibodies with better memory effects.

Recommendation
In Brazil, there are two types of pneumococcal vaccines: the polysaccharide vaccine, and the conjugate vaccines.

What is the importance of S. pneumoniae as a cause of serious respiratory disease?
S. pneumoniae or pneumococcus is a Gram positive bacterium, generally encapsulated, that is present in pairs or short chains in the form of a spear. There are approximately 92 immunologically distinct serotypes capable of leading to various diseases. Of these 92 serotypes, 20 are responsible for 75% of invasive infections.

Pneumococcal infection is classified either as carrier state, noninvasive disease (NID) - localized purulent infection, such as sinusitis, otitis media, conjunctivitis and non-bacteremic pneumonia – or Invasive Pneumococcus Disease (IPD) - pneumonia with bacteremia, bacteremia, meningitis, and endocarditis, which also constitute the forms of presentation in adults and the elderly.

S. pneumoniae is the most frequent agent in community-acquired pneumonia (CAP), varying between 35 and 50% of the cases, ahead of H. influenzae, M. pneumoniae, C. pneumoniae, Legionella sp, respiratory viruses and enterobacteria. As in other parts of the world, S. pneumoniae is also the most common agent for CAP in Latin America (35%). The mortality rate for CAP increases progressively from the age of 60 years, reaching levels 10 times higher than for children less than one year old among individuals aged over 80 years.

IPD has a high morbidity and high mortality rate. Even with pneumococcus vaccination administered to the elderly, there are cases of pneumonia, sometimes complicated with empyema, bacteremia without a defined focus, meningitis, spontaneous bacterial peritonitis, septic arthritis, endocarditis and osteomyelitis. There is also the possibility of a patient having associations with the aforementioned conditions. Mortality within 30 days is 16% and does not depend on the person being vaccinated or not.

The IPD rate changed significantly after the use of conjugate vaccine 7 (PCV7) in children under 5, falling from 252 cases per 100,000 people/year (1991-1997) to 87 cases per 100,000 people/year (2001-2006) or 19-29.9 cases per 100,000 people/year (1998-1999) to 11.2-18 cases per 100,000 people/year. However, the same fact did not occur with the use of pneumococcus vaccine (VPPS-23) in adults, remaining at 60 cases per 100,000 people/year in the first period and 78.9 cases per 100,000 people/year in the second period.

The IPD rate in those aged over 65 years is estimated at 23 cases per 100,000 people/year; however, this increases to 460 cases per 100,000 people/year if the elderly present neoplasms as comorbidity.

Revised Med Br 2014; 60(1):4-15
Considering the substantial morbidity and high rate of early mortality from IPD in adults, work evaluating pneumococcus vaccination defines it as cost effective58,59(B).

**Recommendation**

*S. pneumoniae* causes disease in the respiratory tract, such as high infections (sinusitis and otitis) and pneumonia. It can also lead to meningitis, bacteremia and sepsis. Its capacity for invasiveness produces IPD, which has high morbidity and mortality54,58,59(B).

**What are the recommendations for the pneumococcus vaccine?**
The current recommendation for pneumococcus vaccination by the CDC includes60,61(D):

- all adults aged 65 years or older;
- any person aged from 2 to 64 years with a chronic disease, such as cardiac or pulmonary diseases, sickle cell anemia, diabetes, alcoholism, cirrhosis of the liver, cerebrospinal fistula, or cochlear implants;
- any person between 2 and 64 years of age with immunosuppression conditions such as Hodgkin’s disease, lymphoma or leukemia, kidney failure, multiple myeloma, nephrotic syndrome, HIV infection or AIDS, asplenia or splenic disease and organ transplant;
- any person between 2 and 64 years of age that uses immunosuppressant drugs, such as long term corticosteroid, drugs used in the treatment of cancer, and radiotherapy;
- adults between 19 and 64 years that are smokers or have asthma;
- long-term residents of nursing homes and institutions.

In April, 2013, a new indication of the 13 valent conjugate vaccine was released in Brazil for healthy adults over 50 years. In Brazil, as well as in other locations in the world, vaccine coverage against pneumococcus is still not widely used in clinical practice62-67(B).

The use of electronic reminders for all patients over 65 years could increase the prescription of the pneumococcus vaccine from 13.1 to 19.5%68(B). Another way of increasing the prescription of the vaccine is not to miss the opportunity to vaccinate patients hospitalized for chronic diseases69(B).

**Recommendation**
Pneumococcus vaccines are recommended for the prevention of pneumococcal diseases, especially IPD, in specific groups of adults60,61(D). Programs are required to clarify the importance of the uses of these therapeutic resources to increase the coverage of the vaccine in the population63,64(B).

**Are there differences between polysaccharide and conjugate pneumococcus vaccines?**
The 23-valent polysaccharide vaccine (VPPS-23) presents low immunogenicity in children less than two years old, and does not induce immunological memory as a result of not sensitizing the T cell (T-cell independent activation)69(D). Conjugate vaccines include polysaccharides conjugated to a carrier protein and therefore have greater immunogenic effect, longer immunological memory and provide longer lasting protection. However, having used a polysaccharide vaccine previously reduces the benefits achieved with the conjugate vaccine70(B). For example, as of 2000, the use of the PCV7 vaccine in children less than nine years old resulted in a significant reduction of IPD among vaccinated (direct effect) and unvaccinated individuals of all ages, particularly patients aged over 65 years (herd effect). Two new formulations conjugated with antigens for 10 (PCV10) and 13 (PCV13) serotypes were recently approved in the USA and Brazil for the prevention of IPD in children aged up to two years (PCV10) and children between two months and six years old (PCV13)69(D). The PCV13 was also approved for adults over 50 years.

The general effectiveness of VPPS-23 is 74% (CI 95%, 56%-85%), according to randomized studies, and 52% (CI 95%, 39%-63%), according to observational studies71(D). However, its effectiveness in elderly individuals is inferior to that observed in healthy adults72(B). Also, it enables a significant reduction in IPD (OR=0.26; CI 95% 0.15-0.46)73(A). The effectiveness against all-cause pneumonia has not yet been demonstrated74(A)74(B) and the use of VPPS-23 has not been associated with a lower mortality rate in the vaccinated group (OR=0.87 with CI 95% 0.69-1.10)73(A). The duration of the immune response to VPPS-23 declines with time and age (over 65 years), with the levels of antibodies reaching pre-vaccination levels after 4 to 7 years50,51(B). The benefit of revaccination was demonstra-
Vaccination in the prevention of infectious respiratory diseases in adults

ted in adults under 65 years, with tolerance or hyporesponsiveness possibly occurring\textsuperscript{80,81,74}(B).

We still need robust trials that define the benefits of new conjugate vaccines for adults and the elderly\textsuperscript{77-79}(D).
Pneumococcal vaccination in adults is safe, with few reports of adverse events associated with the injection (transitory pain and redness) and light systemic symptoms such as fever and myalgia, which persist for less than 48 hours. It is not recommended for pregnant women\textsuperscript{57}(B).

Recommendation

There are differences between polysaccharide and conjugate pneumococcus vaccines. Conjugate vaccines produce a longer lasting and more intense immunological response than non conjugate vaccines\textsuperscript{79}(B). VPPS-23 significantly reduces IPD, but up to now, it has not demonstrated a reduction in the amount of pneumonia or mortality\textsuperscript{77-79}(A)\textsuperscript{82}(B), with less benefits for patients over 65 years old\textsuperscript{77-79}(D). There is no benefit in revaccinating adults less than 65 years old, as this may cause tolerance or hyporesponsiveness. There is also discussion about the recommendation for patients with reduced immunity\textsuperscript{80,81,74}(B). Pneumococcus vaccination in adults is safe, with few reports of adverse events, but is not recommended for pregnant women\textsuperscript{57}(B).

**What is the dose and application method of the pneumococcus vaccine?**

The polysaccharide vaccine should be applied in a single dose of 0.5 mL intramuscularly or subcutaneously\textsuperscript{46}(D).

A booster after five years is suggested in patients with reduced immunity, but there is discussion about this recommendation, as studies show a lower antigenic effect after use of the booster dose. The conjugate vaccine PCV13 for adults should be applied in a single dose of 0.5 mL, intramuscularly\textsuperscript{48}(D).

**Is there a benefit to combined vaccinations for the prevention of infectious respiratory diseases in adults?**

Studies on the combine used of flu and pneumococcus vaccines in patients with chronic diseases are common.

Flu and pneumococcus vaccinations are recommended in the Brazilian and global guidelines for heart failure\textsuperscript{77-79}(D), as respiratory infections are the third main cause of hospitalization for decompensated heart failure\textsuperscript{77-79}(D).

Also, there is an association between respiratory infections and increased risk of cardiac ischemia\textsuperscript{80-82}(B) and strokes\textsuperscript{82}(B). These two vaccinations reduce respiratory infections, hospitalizations and acute cardiovascular events\textsuperscript{63}(B).

In order to assess the benefit of 23 polyvalent pneumococcal vaccine in patients with chronic obstructive pulmonary disease (COPD), the number of exacerbations and pneumonia as well as mortality was assessed. There were no significant differences in the number of exacerbations between those vaccinated and unvaccinated (OR=0.58 with CI 95% 0.30-1.13), as well as the number of events of pneumonia (OR=0.72 with CI 95% 0.51-1.01). The evaluation of mortality for all causes within 48 months of vaccination or mortality due to cardiorespiratory causes had no significant differences, either (OR=0.94 with CI 95% 0.67-1.33 and OR=1.07 with CI 95% 0.69-1.66, respectively)\textsuperscript{83}(A). The 23 polyvalent pneumococcus vaccine does not change the frequency and severity of infectious exacerbations in patients with bronchiectasis\textsuperscript{84}(B).

Asthmatic patients present a lower number of specific antibodies after vaccination in relation to non-asthmatics, which keeps them at a high risk of developing IPD, mainly if they depend on corticoids\textsuperscript{85}(B). Using flu vaccine in patients with COPD does not cause adverse reactions, does not lead to exacerbation, does not worsen pulmonary function and the symptoms of dyspnea, and does not increase the restriction on exercise, regardless of any level of obstruction in the air flow\textsuperscript{86}(B).

Patients with COPD should receive vaccination against influenza\textsuperscript{87-89}(B), which reduces mortality in 41% of cases\textsuperscript{80}(B).

There is a benefit to the combined use of flu and pneumococcus vaccines with the reduction of hospitalizations, pneumonia and mortality\textsuperscript{81-84}(B), though the reduction in mortality is influenced more by the protection of the flu vaccine\textsuperscript{89,91}(B).

The use of PCV7 has led to a reduction in the IPD rate in children under 5 with sickle cell anemia, with a reduction in IPD in 93.4% of cases. Before this vaccine (1995-1999) there were 2044 cases per 100,000 people/year and, after the introduction of the vaccine (2001-2004), this number fell to only 134 cases per 100,000 people/year. This benefit was not found for age ranges other than that described, as there were no significant differences in the IPD rate in patients over 5 after use of the conjugate vaccine (161 to 99 cases in 100,000 people/year, with p=0.36)\textsuperscript{92}(B).

Patients with asplenia or splenectomy should receive vaccines for *Haemophilus influenzae* B and pneumococcus vaccine for the increased risk of infection by encapsulated microorganisms, particularly *S. pneumoniae, Haemophilus influenzae tipo B* and *Neisseria meningitidis*. Special care is
necessary in this population, as vaccine coverage might not reach 50% of applicable cases99(B). Splenectomized adults with an average age of 29.6 years already vaccinated with 23 polyvalent polysaccharide vaccine had 5% less cases of IPD in the clinical follow-up, without clinical benefits when adding another PCV7 conjugate vaccination, though with an increase in immunogenic response96(B). Patients splenectomized due to hematologic malignancies respond worse to the polysaccharide pneumococcus vaccines compared to those splenectomized due to trauma, and require closer monitoring97(B).

Given that smoking is associated with an increased risk of respiratory infections, with populations of smokers, former smokers and nonsmokers have been studied to evaluate adherence to the use of flu and pneumococcus vaccines. Former smokers have a 17% greater chance of using flu vaccines than nonsmokers (OR=1.17 with CI 95% 1.12-1.22) and a 32% greater chance of using pneumococcus vaccine than nonsmokers (OR=1.32 with CI 95% 1.24-1.41). Current smokers use these therapeutic resources less (OR=0.75 with CI 95% 0.71-0.80), but should be encouraged to receive the prevention of vaccines and stop using tobacco98(B).

The real benefit of using the pneumococcus vaccine in those with acquired immunodeficiency syndrome is no yet known99(B), as the only randomized clinical trial demonstrated that there was no increase in antibodies after vaccination, whether polysaccharide or conjugate100(A). Likewise, there is debate regarding the use of the vaccine in alcoholics, as there are reported cases of death from streptococcal sepsis after vaccination101,102(C).

There are no studies in adults using pneumococcus vaccines in those with CFS leak syndrome, only in children103(B).

Recommendation
There are benefits in using combined vaccines, as immunization with flu and pneumococcus vaccines reduces hospitalizations, respiratory infections and cardiovascular events in patients with heart disease63(B); and hospitalizations, pneumonia and mortality in those with COPD90,91(B). The association between vaccines for *Haemophius influenzae* B and and pneumococcus reduces the cases of IPD by 5% in patients with asplenia or those splenectomized for all reasons96(B), with a worse response for those splenectomized due to hematologic malignancies97(B). The 93.4% reduction in IPD cases in children less than 5 years old with sickle cell anemia was not confirmed in adult and elderly populations94(B).

**Conflict of interest**
Lundgren F: Received fees for presenting lectures sponsored by Pfizer. He has received medical consultancy fees sponsored by Pfizer.
Chatkin JM: Received reimbursement for appearing at congresses sponsored by the Wyeth and Pfizer. He has received fees for presenting lectures sponsored by the Wyeth and Pfizer.
Corrêa RA: Received reimbursement for appearing at congresses sponsored by Pfizer. He has received fees for the presentation of lectures and medical consultancy sponsored by Pfizer.
Figueiredo MRF: Received reimbursement for medical consultancy and lectures sponsored by Pfizer.
Stirbulov R: Received reimbursement for participating in congresses by GSK, Bohering-Ingelheim and Aché. He has received fees for presentations at symposiums sponsored by Takeda, Pfizer, GSK and Bohering-Ingelheim. He has received fees for medical consultancy sponsored by Bohering-Ingelheim, GSK, Novartis and Aché. He has received fees for clinical research sponsored by Takeda and Novartis.

**References**

6. www.who.int/in Acesso on: 12/16/11.
10. Forrest BD, Steele AD, Hiemstra L, Rappaport R, Ambrose CS, Gruber WC. A prospective, randomized, open-label trial comparing the safety and efficacy...


18. Vaccine package insert for adsorbed vaccine against diphtheria, tetanus, pertussis (acellular). Booster.

19. Package insert for adsorbed vaccine against diphtheria, tetanus, pertussis (acellular) and Polio I, II and III (inactivated).

20. Package insert for adsorbed vaccine against diphtheria, tetanus, pertussis (acellular) and Polio I, II and III (inactivated).


37. Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun 2011;80;1247-50.


43. Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun 2011;80;1247-50.


